Klotho and Mesenchymal Stem Cells: A Review on Cell and Gene Therapy for Chronic Kidney Disease and Acute Kidney Disease.
Marcella Liciani FrancoStephany BeyerstedtÉrika Bevillaqua RangelPublished in: Pharmaceutics (2021)
Chronic kidney disease (CKD) and acute kidney injury (AKI) are public health problems, and their prevalence rates have increased with the aging of the population. They are associated with the presence of comorbidities, in particular diabetes mellitus and hypertension, resulting in a high financial burden for the health system. Studies have indicated Klotho as a promising therapeutic approach for these conditions. Klotho reduces inflammation, oxidative stress and fibrosis and counter-regulates the renin-angiotensin-aldosterone system. In CKD and AKI, Klotho expression is downregulated from early stages and correlates with disease progression. Therefore, the restoration of its levels, through exogenous or endogenous pathways, has renoprotective effects. An important strategy for administering Klotho is through mesenchymal stem cells (MSCs). In summary, this review comprises in vitro and in vivo studies on the therapeutic potential of Klotho for the treatment of CKD and AKI through the administration of MSCs.
Keyphrases
- chronic kidney disease
- mesenchymal stem cells
- acute kidney injury
- end stage renal disease
- oxidative stress
- umbilical cord
- public health
- cardiac surgery
- bone marrow
- cell therapy
- blood pressure
- poor prognosis
- type diabetes
- risk factors
- intensive care unit
- mental health
- case control
- stem cells
- dna damage
- dna methylation
- diabetic rats
- genome wide
- healthcare
- respiratory failure
- binding protein
- hepatitis b virus
- acute respiratory distress syndrome
- skeletal muscle
- insulin resistance
- induced apoptosis
- endoplasmic reticulum stress
- arterial hypertension